Torrent Pharma reported almost flat 1.48% growth in gross revenues for the Dec-20 quarter on consolidated basis at Rs1,995cr. While the overall revenues were flat, the India revenues grew by 7% at Rs930cr. The sales growth in India was largely driven by market recovery, momentum in chronic brands and a very robust recovery in sub-chronic brands. US revenues were sharply down 24% in the quarter on a yoy basis. Brazil revenues also contracted while German revenues grew by 21% yoy.
For the Dec-20 quarter, the consolidated operating profits were up 16.7% at Rs440cr. The company deployed cost optimization measures to improve profitability, which resulted in a sharp fall in miscellaneous expenses. OPM expanded sharply from 19.18% in Dec-19 quarter to 22.06% in Dec-20 quarter.
The consolidated Profit after tax (PAT) for the Dec-20 quarter was up 18.33% at Rs297cr as the operational trickle-down effect helped the bottom line apart from lower interest costs. PAT margins improved from 12.77% in the Dec-19 quarter to 14.89% in the Dec-20 quarter.
Financial highlights for Dec-20 compared yoy and sequentially
|
|
Torrent Pharmaceuticals |
|
|
|
|
Rs in Crore |
Dec-20 |
Dec-19 |
YOY |
Sep-20 |
QOQ |
|
Total Income (Rs cr) |
₹ 1,995.00 |
₹ 1,966.00 |
1.48% |
₹ 2,017.00 |
-1.09% |
|
Operating Profit (Rs cr) |
₹ 440.00 |
₹ 377.00 |
16.71% |
₹ 470.00 |
-6.38% |
|
Net Profit (Rs cr) |
₹ 297.00 |
₹ 251.00 |
18.33% |
₹ 310.00 |
-4.19% |
|
|
|
|
|
|
|
|
Diluted EPS (Rs) |
₹ 17.52 |
₹ 14.77 |
|
₹ 18.32 |
|
|
OPM |
22.06% |
19.18% |
|
23.30% |
|
|
Net Margins |
14.89% |
12.77% |
|
15.37% |
|
Related Tags: